Page 8 - CUA FALL 2020 NEWSLETTER

Office of Education

As the CUA Office of Education continues to meet 4) Monthly journal club
our member’s educational needs, we constantly 5) Invited speaker of the month
strive to do better. In late August, Dr. Ricardo Rendon
assembled an educational focus group comprised of: 6) Podcasts
Naeem Bhojani, Ashley Cox, Girish Kulkarni, Jason Lee, 7) Point/counterpoint debates
Michael Leveridge, Keith Rourke, Alan So, and
Tiffany Pizioli. 8) Resident basic science course
Many educational ideas and platforms were 9) Regional meetings
discussed, and the following are endeavors that the 10) Community urology mentorship program
group agreed would add value to the membership:
Look for these programs coming in the next year!
1) Annual meeting
If you have any suggestions for programs, please
2) Orphan topic bank of programs
contact tiffany.pizioli@cua.org
3) Surgical courses discussing cases with video

Help Your MYRBETRIQ ® is the MYRBETRIQ —the only selective
®
dispensed
OAB Patients OAB 2* β3 adrenoceptor agonist
medication
across Canada
Fight the Urge indicated in OAB *
Consult the product monograph at https://health-products.canada.ca/dpd-
bdpp/index-eng.jsp for important information about:
• Contraindications in patients with severe uncontrolled hypertension
(SBP ≥180 mm Hg and/or DBP ≥110 mm Hg) and in pregnancy
• Relevant warnings and precautions relating to serious adverse events of
neoplasm (0.1%, reported in a study with MYRBETRIQ 50 mg ); serum
#
®
ALT/AST increase (0.3%, reported in a study with MYRBETRIQ 50 mg )
®
#
with/without bilirubin increase and Stevens–Johnson syndrome; risk of
cardiovascular effects (dose dependent QTc prolongation, elevated blood
pressure, elevated heart rate); use in patients with clinically significant
bladder outlet obstruction, hepatic or renal impairment, or risk factors for
torsade de pointes; use in patients taking medications known to prolong
the QT interval or antimuscarinics for OAB; interaction with CYP2D6
substrates; ophthalmological examinations in patients with glaucoma;
and use during nursing
• Conditions of clinical use, adverse reactions, drug interactions and
dosing instructions
The Product Monograph is also available by calling us at 1-888-338-1824.
References:
MYRBETRIQ (mirabegron) is indicated for the treatment of 1. MYRBETRIQ ® Product Monograph. Astellas Pharma Canada Inc. June 2, 2016.
®
overactive bladder (OAB) with symptoms of urgency, urgency 2. IQVIA. Canadian CompuScript Data. July 2019.
incontinence and urinary frequency. 1 * Comparative clinical significance unknown.
# A 1-year, randomized, fixed-dose, double-blind, active-controlled safety study in patients
with OAB in which MYRBETRIQ ® was evaluated for safety in 1,632 patients who received
MYRBETRIQ ® 50 mg OD (n=812 patients) or MYRBETRIQ ® 100 mg (n=820 patients); the
Choose MYRBETRIQ for your OAB patients 100 mg strength is not available in Canada. Patients received MYRBETRIQ ® continuously
®
for at least 6 months (n=1,385), 9 months (n=1,311) or 1 year (n=564).
MYRBETRIQ ® is a trademark of Astellas Pharma Canada, Inc.
8